A new public-private partnership – COVIDRIVE – announced today that it will begin studies to assess the effectiveness of multiple COVID-19 vaccines in Europe to support the region’s public health response and to address the vaccine companies’ regulatory obligations. This multi-stakeholder partnership brings together public institutions, small medium enterprises and vaccine companies, including FISABIO (Spain), P95 (Belgium), THL (Finland), AstraZeneca (UK), CureVac (Germany), Janssen (Belgium), Sanofi-Pasteur (France) and GSK (Belgium).

The partnership will conduct several studies to analyse COVID-19 vaccine effectiveness in real-world conditions to complement what is known from robust clinical trials conducted for marketing authorisations. In addition to overall effectiveness for each brand of vaccine, key areas of interest include: duration of vaccine protection, effectiveness against disease caused by newly emerging SARS-CoV-2 strains, effectiveness against severe COVID-19 disease and effectiveness in special risk groups such as immunocompromised, frail individuals or subjects with chronic conditions or existing comorbidities.

COVIDRIVE will leverage an existing influenza vaccine effectiveness platform (DRIVE), which has provided annual brand-specific influenza vaccine effectiveness estimates to the European Medicines Agency (EMA) since 2017.

AstraZeneca and Janssen will be the first pharmaceutical companies in the partnership to launch their brand-specific COVID-19 vaccine effectiveness assessments through COVIDRIVE, starting in July 2021.
For more details on COVIDRIVE please check our website https://covidrive.eu

If you would like to request a COVID-19 vaccine effectiveness study and/or participate as a partner/study site in COVIDRIVE, send an email to COVIDRIVE Coordination team (info@covidrive.eu)